🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Poland / NCT06793085
Recruiting Observational

Pro- and Anti-inflammatory Cytokines in PCOS

NCT06793085 · tracked via the Priya Life Science Poland tracker
Phase
Observational
Started
2025-01-20
Last updated
2026-03-18

Condition(s) studied

Reproductive AgePCOS (Polycystic Ovary Syndrome)

Investigational drug(s) / intervention(s)

Measurement of interleukin-6 (il-6) concentration in blood serumMeasurement of fasting tumor necrosis factor α (TNF-α) concentrationMeasurement of interleukin-18 (il-18) concentrationMeasurement of interleukin-4 (il-4) concentration

Measurement of interleukin-6 (il-6) concentration in blood serum: Measurement of fasting interleukin-6 (il-6) concentration in fasting venous blood serum

Measurement of fasting tumor necrosis factor α (TNF-α) concentration: Measurement of fasting tumor necrosis factor α concentration in fasting venous blood serum

Measurement of interleukin-18 (il-18) concentration: Measurement of interleukin-18 (il-18) concentration in fasting venous blood serum

Measurement of interleukin-4 (il-4) concentration: Measurement of interleukin-4 (il-4) concentration in fasting venous blood plasma

Study summary

The study will involve measurements and comparisons of the concentrations of pro-inflammatory cytokines: IL-6, TNF-α, IL-18, as well as anti-inflammatory cytokine IL-4 in women with polycystic ovary syndrome (PCOS) and insulin resistance, women with polycystic ovary syndrome without carbohydrate metabolism disorders, and women without PCOS (control group).

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * women aged 18-45 years Exclusion Criteria: * previous removal of at least one ovary * treated diabetes of any type * diagnosed and treated metabolic diseases * diagnosed and treated autoimmune diseases * diagnosed and treated autoinflammatory diseases

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Jagiellonian University Krakow Poland Recruiting

More Jagiellonian University trials in Poland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06793085 on ClinicalTrials.gov ↗ ← All trials in Poland